FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079503537> ?p ?o ?g. }

• W2079503537 endingPage "329" @default.
• W2079503537 startingPage "315" @default.
• W2079503537 abstract "Tumor cells have developed multiple mechanisms to evade control by the immune system. Tumoral cells expressing Fas ligand (FasL) have been proposed to counterattack against activated antitumoral effector immune cells, although some authors have indicated that FasL is not expressed on the surface of the same tumors, such in the case of melanoma cells. However, other factors could be implicated, such as the balance of soluble versus membrane-bound forms or the secretion of death ligands on the surface of microvesicles, as described previously by our group in human T cells. In the present study, we analyzed the expression and secretion of FasL and APO2 ligand (APO2L)/TRAIL in the human melanoma cell line MelJuSo. We have observed the expression of preformed FasL and APO2L/TRAIL in these cells, their secretion associated with microvesicles upon melanoma activation with PHA or with alpha-melanocyte stimulating hormone (alpha-MSH), and the toxicity of these microvesicles against normal human T cell blasts. We have also observed that the mechanism of secretion of FasL and APO2L/TRAIL from melanoma cells is depending both on microtubules and actin filaments. From these data, it can be concluded that the MelJuSo melanoma cell line has the possibility to counterattack against activated immune effector cells. However, the in vivo outcome seems more complex since it has been also described that FasL expressed in tumors has a proinflammatory effect." @default.
• W2079503537 created "2016-06-24" @default.
• W2079503537 creator A5004768391 @default.
• W2079503537 creator A5033737374 @default.
• W2079503537 creator A5039666961 @default.
• W2079503537 creator A5050926473 @default.
• W2079503537 creator A5059782439 @default.
• W2079503537 creator A5078936429 @default.
• W2079503537 creator A5082187879 @default.
• W2079503537 date "2004-05-01" @default.
• W2079503537 modified "2023-10-18" @default.
• W2079503537 title "The human melanoma cell line MelJuSo secretes bioactive FasL and APO2L/TRAIL on the surface of microvesicles. Possible contribution to tumor counterattack" @default.
• W2079503537 cites W117605483 @default.
• W2079503537 cites W1482540117 @default.
• W2079503537 cites W1517945724 @default.
• W2079503537 cites W1527985047 @default.
• W2079503537 cites W1527997848 @default.
• W2079503537 cites W1528349069 @default.
• W2079503537 cites W1567676800 @default.
• W2079503537 cites W1572252257 @default.
• W2079503537 cites W1600015917 @default.
• W2079503537 cites W1615638781 @default.
• W2079503537 cites W1620218395 @default.
• W2079503537 cites W1625007357 @default.
• W2079503537 cites W1639310471 @default.
• W2079503537 cites W1662505552 @default.
• W2079503537 cites W1838640007 @default.
• W2079503537 cites W1874379912 @default.
• W2079503537 cites W1889489351 @default.
• W2079503537 cites W1963754854 @default.
• W2079503537 cites W1973988039 @default.
• W2079503537 cites W1975291295 @default.
• W2079503537 cites W1988689320 @default.
• W2079503537 cites W1993199753 @default.
• W2079503537 cites W1996980134 @default.
• W2079503537 cites W2016198585 @default.
• W2079503537 cites W2028248159 @default.
• W2079503537 cites W2030389529 @default.
• W2079503537 cites W2031469085 @default.
• W2079503537 cites W2041302454 @default.
• W2079503537 cites W2041466047 @default.
• W2079503537 cites W2046263965 @default.
• W2079503537 cites W2056217426 @default.
• W2079503537 cites W2056924500 @default.
• W2079503537 cites W2064706357 @default.
• W2079503537 cites W2076656122 @default.
• W2079503537 cites W2080879611 @default.
• W2079503537 cites W2081500438 @default.
• W2079503537 cites W2083765379 @default.
• W2079503537 cites W2084289122 @default.
• W2079503537 cites W2094201721 @default.
• W2079503537 cites W2098712005 @default.
• W2079503537 cites W2107452159 @default.
• W2079503537 cites W2109721791 @default.
• W2079503537 cites W2110952822 @default.
• W2079503537 cites W2121222760 @default.
• W2079503537 cites W2121462531 @default.
• W2079503537 cites W2121738805 @default.
• W2079503537 cites W2122635106 @default.
• W2079503537 cites W2130988210 @default.
• W2079503537 cites W2141003137 @default.
• W2079503537 cites W2142598717 @default.
• W2079503537 cites W2148974388 @default.
• W2079503537 cites W2149619554 @default.
• W2079503537 cites W2155366992 @default.
• W2079503537 cites W2159531745 @default.
• W2079503537 cites W2168747001 @default.
• W2079503537 cites W2168945225 @default.
• W2079503537 cites W2169439167 @default.
• W2079503537 cites W2412694917 @default.
• W2079503537 doi "https://doi.org/10.1016/j.yexcr.2003.12.024" @default.
• W2079503537 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15093732" @default.
• W2079503537 hasPublicationYear "2004" @default.
• W2079503537 type Work @default.
• W2079503537 sameAs 2079503537 @default.
• W2079503537 citedByCount "81" @default.
• W2079503537 countsByYear W20795035372012 @default.
• W2079503537 countsByYear W20795035372013 @default.
• W2079503537 countsByYear W20795035372014 @default.
• W2079503537 countsByYear W20795035372015 @default.
• W2079503537 countsByYear W20795035372016 @default.
• W2079503537 countsByYear W20795035372017 @default.
• W2079503537 countsByYear W20795035372018 @default.
• W2079503537 countsByYear W20795035372019 @default.
• W2079503537 countsByYear W20795035372020 @default.
• W2079503537 countsByYear W20795035372021 @default.
• W2079503537 countsByYear W20795035372022 @default.
• W2079503537 countsByYear W20795035372023 @default.
• W2079503537 crossrefType "journal-article" @default.
• W2079503537 hasAuthorship W2079503537A5004768391 @default.
• W2079503537 hasAuthorship W2079503537A5033737374 @default.
• W2079503537 hasAuthorship W2079503537A5039666961 @default.
• W2079503537 hasAuthorship W2079503537A5050926473 @default.
• W2079503537 hasAuthorship W2079503537A5059782439 @default.
• W2079503537 hasAuthorship W2079503537A5078936429 @default.
• W2079503537 hasAuthorship W2079503537A5082187879 @default.
• W2079503537 hasConcept C104317684 @default.
• W2079503537 hasConcept C134018914 @default.

• next